Efficacy and safety profile of 2-year netakimab treatment in patients with moderate-to-severe plaque psoriasis in terms of the randomized double-blind placebo-controlled BCD-085-7/PLANETA clinical trial

Efficacy and safety profile of 2-year netakimab treatment in patients with moderate-to-severe plaque psoriasis in terms of the randomized double-blind placebo-controlled BCD-085-7/PLANETA clinical trial

Background. Netakimab, a recombinant humanized monoclonal antibody, specifically binding to IL-17 blocks its activity resulting in plaque psoriasis signs decrease. The results of the first year of BCD-085-7/PLANETA study showed high efficacy and a favorable safety profile in the treatment of patient...

Full description

Bibliographic Details
Main Authors: Andrey I. Bakulev, Alexey V. Samtsov, Evgeny V. Sokolovskiy, Muza M. Kokhan, Marianna M. Khobeish, Vladislav R. Khairutdinov, Arfenya E. Karamova, Olga U. Olisova, Dmitry V. Ignatiev, Aleksandra N. Nikiforova, Antonina V. Artemeva, Arina V. Zinkina-Orikhan
Format: Article
Language:English
Published: State Scientific Center of Dermatovenereology and Cosmetology 2022-05-01
Series:Vestnik Dermatologii i Venerologii
Subjects:
netakimab
psoriasis
humanized monoclonal antibody
adverse events
Online Access:https://vestnikdv.ru/jour/article/viewFile/1306/pdf

Internet

https://vestnikdv.ru/jour/article/viewFile/1306/pdf

Similar Items